Medipharm Labs Corp (LABS : TSX)
Common Stock
$0.08
CAD
-0.01 (-13.89%)
Last updated: 2026-07-17
LABS
Medipharm Labs Corp
WealthAwesomePerformance
1 Day
-13.89%
1 Week
+3.33%
1 Month
+10.71%
YTD
+10.71%
Key Statistics
Market Cap
$32.93M
52W High
$0.10
52W Low
$0.06
P/E Ratio
-
50 Day MA
$0.08
200 Day MA
$0.07
Beta
0.92
Dividend Yield
-
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 7/17/2026 | $0.09 | $0.09 | $0.07 | $0.08 | $0.08 | 803,146 |
| 7/16/2026 | $0.09 | $0.09 | $0.08 | $0.09 | $0.09 | 1,135,557 |
| 7/15/2026 | $0.08 | $0.09 | $0.08 | $0.09 | $0.09 | 497,572 |
| 7/14/2026 | $0.07 | $0.08 | $0.07 | $0.07 | $0.07 | 551,641 |
| 7/13/2026 | $0.07 | $0.07 | $0.07 | $0.07 | $0.07 | 6,479 |
| 7/10/2026 | $0.07 | $0.07 | $0.07 | $0.07 | $0.07 | 85,184 |
| 7/9/2026 | $0.07 | $0.07 | $0.07 | $0.07 | $0.07 | 86,104 |
| 7/8/2026 | $0.07 | $0.07 | $0.07 | $0.07 | $0.07 | 71,363 |
| 7/7/2026 | $0.07 | $0.07 | $0.07 | $0.07 | $0.07 | 3,075 |
| 7/6/2026 | $0.07 | $0.07 | $0.07 | $0.07 | $0.07 | 60,333 |
Analyst Price Targets
Based on analyst covering LABS
Wall Street analysts forecast LABS stock price to rise 29.0% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$0.10
+29.0% Upside
Current Price
C$0.08
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on LABS's historical volatility
30-Day Vol
88.6%
Annualized
90-Day Vol
84.1%
Annualized
Trend (90d)
+42.7%
Annualized drift
90d Mean
C$0.09
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.08 | C$0.06 – C$0.11 |
| 60 trading days | C$0.09 | C$0.06 – C$0.13 |
| 90 trading days | C$0.09 | C$0.05 – C$0.15 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Medipharm Labs Corp
MediPharm Labs Corp. operates as a pharmaceutical company that produces and sells purified, pharmaceutical-like cannabis extracts, concentrates, active pharmaceutical ingredients, and advanced derivative products in Canada, Australia, Germany, and internationally. The company formulates, processes, packages, and distributes cannabis active ingredients and advanced cannabinoid-based products. It also provides good manufacturing practice flower sourcing, packaging, and distribution services, as well as dried flower, pre-roll, and other cannabis products. In addition, the company offers cannabis related medical information and services; and cannabis clinic services for patients requiring medical cannabis education and prescriptions. MediPharm Labs Corp. was founded in 2015 and is based in Barrie, Canada.
Financials
- Revenue (TTM)
- $43.28M
- EBITDA
- $-6.20M
- Profit Margin
- -20.21%
- ROE (TTM)
- -22.33%
- EPS (Diluted)
- -0.02
- Book Value
- 0.08
Classification
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
Advertisement
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Common Questions About LABS
Articles Featuring LABS.TO
Latest articles and analysis covering LABS.TO
Why Medipharm Labs Corp stock is plummeting today
Medipharm Labs Corp's stock plummeted by nearly 14% today, closing at CA$0.08. This decline follows the announcement of positive results from a Phase II clinical trial, highlighting the disconnect between clinical success and market performance.
Why Medipharm Labs Corp stock is skyrocketing today
Medipharm Labs Corp's stock has surged by 5.88% following the announcement of positive Phase II trial results that could significantly impact treatment options for patients with advanced dementia.
Why Medipharm Labs Corp stock is skyrocketing today
Medipharm Labs Corp has surged by 13.33% today following the announcement of positive Phase II trial results for its cannabinoid formulation aimed at treating agitation in dementia patients. This milestone could pave the way for future growth and partnerships.
What's Going On With Medipharm Labs Corp Stock Wednesday?
Medipharm Labs Corp has seen its stock price increase by 7.14% this week, driven by positive news regarding its clinical trials for Alzheimer’s treatment. The company continues to navigate financial challenges but may benefit from heightened investor interest.
Why Medipharm Labs Corp stock is skyrocketing today
Medipharm Labs Corp (LABS.TO) has surged 6.67% in one trading day, driven by positive Phase II trial results for its cannabinoid formulation targeting agitation in dementia patients.
Why Medipharm Labs Corp stock is plummeting today
Medipharm Labs Corp's stock has taken a significant hit, closing down 13.33% today. Investors are left to ponder the implications of this decline amid ongoing challenges in the cannabis sector.
Why Medipharm Labs Corp stock is skyrocketing today
Medipharm Labs Corp's stock surged by 7.14% today, driven by strong revenue growth and strategic market positioning. Investors should consider both the opportunities and risks as the company continues to evolve in the cannabis industry.
Why Medipharm Labs Corp stock is skyrocketing today
Medipharm Labs Corp's stock soared by 7.69% in the last trading session, driven by positive developments in its international operations and market expansion efforts.
Why Medipharm Labs Corp stock is skyrocketing today
Medipharm Labs Corp's stock price surged by 7.69% in the last trading session, reflecting positive investor sentiment and the company's ongoing expansion efforts in the medical cannabis market.
Why Medipharm Labs Corp stock is skyrocketing today
Medipharm Labs Corp's stock has jumped by over 7% in a single trading day, driven by strategic developments and a favorable regulatory landscape in the cannabis industry.
Why Medipharm Labs Corp stock is skyrocketing today
Medipharm Labs Corp's stock has gained 7.14% in the latest trading session, closing at CA$0.07. This rise may signal growing investor confidence as the company positions itself for future growth in the cannabis sector.
Why Medipharm Labs Corp stock is skyrocketing today
Medipharm Labs Corp's stock surged by 7.14% in the last trading session, driven by positive developments from its recent shareholder meeting and a strategic focus on growth in the medical cannabis sector.
Why Medipharm Labs Corp stock is plummeting today
Medipharm Labs Corp's stock has plummeted by 6.67% in the latest trading session, closing at CA$0.07. This decline is a stark reminder of the volatility in the cannabis sector and the challenges faced by companies in this space.
Why Medipharm Labs Corp stock is plummeting today
Medipharm Labs Corp's stock has taken a hit, dropping 6.67% in the latest trading session. Investors are left to ponder the implications of this decline in the context of the company's overall financial health and market position.
Why Medipharm Labs Corp stock is plummeting today
Medipharm Labs Corp's stock plummeted by 6.67% today, closing at CA$0.07. This decline raises questions about the company's future performance as it navigates a challenging market landscape.
Why Medipharm Labs Corp stock is skyrocketing today
Medipharm Labs Corp's stock has jumped 7.14% in the last trading session, reflecting investor optimism fueled by recent positive financial results and operational efficiencies.
Why Medipharm Labs Corp stock is skyrocketing today
Medipharm Labs Corp's stock surged 7.14% in the last trading session, driven by optimism surrounding new U.S. cannabis policies and the company's operational improvements.
Why Medipharm Labs Corp stock is skyrocketing today
Medipharm Labs Corp's stock has surged by 7.14% in the last trading session, closing at CA$0.07. This uptick is attributed to the company's strategic moves in the cannabis market, including international shipments and potential regulatory changes in the U.S.
Why Medipharm Labs Corp stock is skyrocketing today
Medipharm Labs Corp's stock surged by over 7% in the last trading session, driven by its expanding footprint in the international medical cannabis market.
